Symbiosis Starts Producing Sevuparin for Modus Therapeutics’ Future Clinical Development in Sepsis/Septic Shock

Symbiosis Starts Producing Sevuparin for Modus Therapeutics’ Future Clinical Development in Sepsis/Septic Shock

We’re very proud to announce that Symbiosis is working with Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, to manufacture their sevuparin drug product, securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation.

Click here to find out more about this partnership: https://www.modustx.com/press-release?releaseIdentifier=F1DBF85B7C62D6DC

Sign up to our Newsletter

Fill in your details to be added to our mailing list and receive our latest updates.